Unfortunately, the effectiveness of chemotherapy for liver cancer is not very good, which is related to the special characteristics of the liver, as the liver is a relatively immune organ to chemotherapy drugs in the whole body. At present, the systemic intravenous chemotherapy recommended in the guidelines for liver cancer is mainly oxaliplatin plus fluorouracil, and even if the recommended regimen in the guidelines is longer than the survival without treatment, it is only about 2-3 months longer. So, overall, the effect of common chemotherapy for liver cancer is not good. Therefore, the main application of chemotherapy for liver cancer is with TACE, which is the so-called hepatic artery chemoembolization. This method is to hit the drug to the local area of liver tumor to form a local dose of highly concentrated chemotherapy drug, which can play the role of killing the tumor and can effectively prolong the survival of liver cancer patients. At the same time, it should be combined with other treatments, such as radiotherapy and TACE treatment before surgery after the liver tumor shrinks.